hrp0094p2-26 | Adrenals and HPA Axis | ESPE2021

Testicular adrenal rest tumour in children with classical congenital adrenal hyperplasia: A case series.

Peng Cheng Hooi , Sze Lyn Wong Jeanne , Suffian Hassim Mohamad , Arliena Mat Amin Noor , Selveindran Nalini M , Guang Gan Cheng , Teik Teoh Sze , Anand L Alexis , Hua Hong Janet Yeow ,

Introduction: Testicular adrenal rest tumour (TART) is a complication in males with congenital adrenal hyperplasia (CAH). However, the prevalence, risk factors and treatment in children are not clear.Objective: 1) To identify the incidence of TART and risk factors in patients with classical CAH in our centre 2) To study the clinical characteristics, hormonal profile, treatment interventions and outcome of patients with T...

hrp0097t8 | Section | ESPE2023

Design and Objectives of the Acorn Study: A Non-Interventional Study Evaluating Long-term Safety in Achondroplasia Patients Treated with Vosoritide

M Pimenta Jeanne , Cohen Shelda , Mukherjee Swati , Fettes Fiona , Jayaram Kala , Lausch Ekkehart , Mallya Usha G. , Min Yang , Caroline Huber , Cala Mary Lynn , Ali Greatsinger , Jeremy Pomeroy , Haqq Andrea M.

Introduction: Achondroplasia is caused by a pathogenic mutation in the FGFR3 gene, leading to impaired endochondral bone growth and multiple medical complications. Vosoritide, a modified recombinant human C-type natriuretic peptide (rhCNP), was approved by the European Medicines Agency (EMA) in August 2021 for treating genetically confirmed achondroplasia in patients aged ≥2 years until closure of epiphyses. Acorn is the first treatment-based registry for a...

hrp0092p1-77 | GH and IGFs | ESPE2019

Severe IGF-I Deficiency in Children with Normal Growth Hormone (GH) Secretion and Excluded GH Insensitivity – is it Really Idiopathic Short Stature?

Joanna Smyczynska , Urszula Smyczynska , Andrzej Lewinski , Maciej Hilczer

According to current recommendations, children with height SDS <-3.0, normal growth hormone (GH) peak in stimulation tests (stimGH) and severe IGF-I deficiency (IGFD) may be diagnosed with primary IGFD and treated with recombinant IGF-I. The need for direct confirmation of GH insensitivity is a matter of discussion. On the other hand, children born small for gestational age (SGA) with no catch-up growth are qualified to GH therapy despite normal GH secretion. The fact that...

hrp0092p2-134 | Fat, Metabolism and Obesity | ESPE2019

Tumor Necrosis Factor Alpha in Metabolic Syndrome Development in Children

Ben-Skowronek Iwona , Kapczuk Iga , Mroczek Wacinska Joanna

Background: Tumor necrosis factor alpha (cachexin) is a cell signaling cytokine involved in systemic inflammation process. It is produced chiefly by activated macrophages, although it can be produced by many other cell types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons. The primary role of TNF alpha is the regulation of immune cells. TNF, being an endogenous pyrogen, is able to induce fever, apoptotic cell death, an...

hrp0089p2-p235 | GH &amp; IGFs P2 | ESPE2018

Hormonal Predictors of Growth Hormone Therapy Effectiveness in Children with Short Stature – Evidence from Neural Prediction Model for Final Height

Hilczer Maciej , Smyczynska Joanna , Urszula Smyczynska , Stawerska Renata , Lewinski Andrzej

Prediction of growth hormone (GH) therapy effectiveness in children with short stature is an important issue for optimizing its course. Recently, our research group has published prediction models derived with neural networks. The main predictors of final height (FH) in our model were: patient’s height SDS at therapy onset, pre-treatment change of height SDS (HSDS V0) and pre-treatment IGF-I and IGFBP-3 secretion but not the results of GH stimulation tests; the...

hrp0089p2-p237 | GH &amp; IGFs P2 | ESPE2018

Predictors of Poor Response to Growth Hormone Therapy in Children with Short Stature – Evidence from Neural Prediction Model for Final Height

Smyczynska Joanna , Smyczynska Urszula , Hilczer Maciej , Stawerska Renata , Lewinski Andrzej

Prediction of poor response to growth hormone (GH) therapy in children with short stature is an important issue for personalized approach to treatment. Recently, our research group has published prediction models derived with neural networks. The main predictors of final height (FH) in our model were: patient’s height SDS at therapy onset (H0SDS) and pre-treatment IGF-I and IGFBP-3 concentrations but not the results of GH stimulation tests; pre-treatment growth...

hrp0089p3-p266 | Multisystem Endocrine Disorders P3 | ESPE2018

Assessment of Ovarian Reserve in Young Women with Hashimoto Disease – The Pilot Study

Wedrychowicz Anna , Wojtyś Joanna , Stelmach Malgorzata , Starzyk Jerzy B

Introduction: Human ovary is commonly the target of an autoimmune attack in cases of organ- or non-organ-specific autoimmune disorders. Hashimoto’s thyroiditis (HT) is likely to be associated with ovarian dysfunction and diminished ovarian reserve. The classical hormonal test assessing ovarian reserve as early follicular phase serum levels of FSH, inhibin B and estradiol (E2), which are interdependent, and the calculation of the number of antral follicles by transvaginal ...

hrp0089p1-p263 | Thyroid P1 | ESPE2018

Expression of ZnT8 Transporter in Thyroid Tissues from Patients with Immune and Non-Immune Thyroid Diseases

Bossowski Artur , Reszec Joanna , Polnik Dariusz , Gasowska Marta , Niklinska Wieslawa

Introduction: Zinc homeostasis is regulated by ZnT and Zip zinc transporters. Zinc transporter 8 (ZnT8) is localized in insulin containing secretory granule membrane and transports zinc from the cytosol into the vesicles. ZnT8 was identified on peripheral lymphocytes, in subcutaneous adipose tissue, in a pancreatic β-cells and extra-pancreatic endocrine glands including pituitary, adrenal and thyroid. Autoantibodies to the ZnT8 are detected in the majority of type 1 diabe...

hrp0086p1-p626 | Growth P1 | ESPE2016

Significance of IGF-I Generation Test in Diagnosing Primary and Non-Primary IGF-I Deficiency – Clinical Considerations

Smyczynska Joanna , Smyczynska Urszula , Stawerska Renata , Lewinski Andrzej , Hilczer Maciej

Background: The diagnosis of severe primary IGF-I deficiency (IGFD) in children with normal growth hormone (GH) peak in stimulation tests (stimGH) should be confirmed by IGF-I increase <15.0 ng/ml during generation test (IGF-GT), however the significance of IGF-GT has been questioned by some researchers.Objective and hypotheses: Evaluation of the significance of IGF-GT in children with normal stim GH and IGFD, with respect to efficacy of growth-promo...

hrp0082p2-d2-429 | Growth Hormone (1) | ESPE2014

What Should be the Diagnosis and Management of Short Children with IGF1 Deficiency, Responding to GH Administration Despite Normal GH Secretion?

Smyczynska Joanna , Stawerska Renata , Lewinski Andrzej , Hilczer Maciej

Background: GH deficiency (GHD) is currently defined as secondary IGF1 deficiency (IGFD). In the patients with normal GH secretion and IGFD, significant increase of IGF1 during generation test excludes primary IGFD, however is not an approved indication for GH therapy.Objective and hypotheses: The aim of the study was to assess GH therapy effectiveness in children with IGFD, responding to short-term GH administration despite normal GH peak after falling ...